Contact Us Contact Us Contact Us

Updated July 2026

Pharma Guide · Buyer Checklist

6 Things to Check Before Choosing a Cardiovascular Medicine Manufacturer in India

Cardiovascular disease is the leading cause of mortality globally, responsible for approximately 17.9 million deaths annually (WHO, 2023). Cardiovascular medicines are chronic-therapy products — patients take them for years, not days — which raises the bar on consistency and documentation compared to acute-use medicines. Six specific checks reflect what actually matters when sourcing a long-term supply partner, not just a one-time order.

  • 10 companies reviewed
  • WHO-GMP verified criteria
  • 14 min read

  • WHO-GMP Status

    Active cert — not expired

  • Sample COA

    real batch data, 24 hours

  • DCGI Approvals

    molecule-level approval

  • COPP on file

    for your target country

  • Grade A/B cleanroom

    sterile injectable

  • Written by

    Bhavya Bhambani

    Content Writer, 9M India

  • Reviewed by

    Manish Agrawal

    MD, 9M India Limited

  • Fact-checked by

    Manish Shah

    Plant Head, 9M India

About 9M India Limited — examples and standards referenced in this guide

9M India Limited is a WHO-GMP certified pharmaceutical manufacturer established in 2009, located in Birkoni, District Mahasamund, Chhattisgarh. The company holds DCGI-approved manufacturing licences for cardiovascular medicines across 200+ molecules, including antihypertensives, statins, antiplatelet agents, and fixed-dose combinations. This guide uses 9M India’s documentation standards as the benchmark — COPP, FSC, COA, and stability data available within 24 hours, exports to 15+ countries.

Why these 6 checks matter — industry context

Cardiovascular disease is responsible for approximately 17.9 million deaths annually worldwide (WHO, 2023), and India is a major supplier of cardiovascular generic medicines — antihypertensives, statins, antiplatelet agents, and cardiac glycosides — to Africa, Middle East, and South-East Asia markets where non-communicable disease burden is rising. A verification challenge specific to cardiovascular medicine: because these are long-term, repeat-order chronic therapies rather than one-time-use products, supply consistency and combination-specific DCGI approval matter more here than for acute-use categories, where a single successful shipment tells you less about long-term reliability. These six checks are the practical buyer’s verification framework, drawn from the documentation requirements of NAFDAC (Nigeria), MOH UAE, and WHO prequalification guidelines.

WHO-GMP Certification

Verify the WHO-GMP certificate expiry date — critical for a multi-year supply relationship

For a chronic-therapy product with repeat orders over years, a certificate lapsing mid-relationship is a real operational risk.

#1 of 6

Request the actual WHO-GMP certificate document and check the issue date and expiry directly. Given cardiovascular medicine sourcing is typically a long-term, repeat-order relationship, confirm re-audit timing upfront — you’ll want visibility into when the certificate needs renewal well before it happens.

What is WHO-GMP certification in India?

WHO-GMP is a pharmaceutical-specific manufacturing standard covering facility design, water systems, air handling, process validation, analytical QC, and batch documentation, issued by CDSCO following facility inspection. It is time-limited and requires periodic re-inspection to remain valid.

How to verify — step by step

  • Request the actual document: PDF or scan on official CDSCO letterhead.

  • Check the expiry date and ask about re-audit timing: Given this is likely a multi-year relationship, understand the renewal cycle upfront.

  • Confirm dosage forms covered: The certificate should list solid oral dosage or injectable manufacturing as relevant to your cardiovascular product.

  • Cross-verify on CDSCO database: Cross-reference at cdsco.gov.in using the licence number.

9M INDIA
the active WHO-GMP certificate is issued by CDSCO, with clear re-audit timelines communicated to long-term supply partners, available within 24 hours of any enquiry.

Red flags to watch for

Certificate older than 3 years with no re-inspection documentation  ·  No clarity on upcoming renewal timing  ·  Certificate doesn’t list your required dosage form  ·  Manufacturer cannot provide certificate within 24 hours

From Industry Rankings

See how the top 10 tablet manufacturers in India compare on WHO-GMP status

Our editorial ranking compares the top 10 tablet manufacturers in India across all 6 criteria in this guide — WHO-GMP status, dosage-form range, DCGI approvals, export track record, documentation speed, and FDC capability.

See the full ranking

FDC Approval

Confirm DCGI approval for your specific molecule AND combination, if applicable

Amlodipine+Atenolol and Amlodipine+Telmisartan are separate DCGI approvals — not variations of the same one.

#2 of 6

Cardiovascular fixed-dose combinations — such as Amlodipine+Atenolol or Telmisartan+Amlodipine — require a specific DCGI licence for that exact combination, separate from individual molecule approvals. Confirm your specific combination and strength is covered before finalising.

Why FDC approval is especially common — and especially important — in cardiovascular medicine

Cardiovascular therapy frequently uses combination products to manage multiple risk factors (blood pressure, cholesterol) with a single pill for patient adherence — making FDC approval verification a routine, not exceptional, part of sourcing in this category. Some combinations may be restricted under Section 26A of the Drugs and Cosmetics Act.

How to verify — step by step

  • Request the FDC-specific DCGI licence: Not individual molecule approvals — the combination approval document itself.

  • Confirm the exact ratio matches your requirement: Different strength combinations are separate approvals.

  • Check Section 26A restricted list: Confirm your specific combination isn’t restricted.

  • Ask how long the FDC approval has been active: Longer-standing approvals typically have more established supply and export history.

Why this check matters for export

Import regulators check the DCGI licence against the exact combination filed in the dossier — a mismatch between individually-approved molecules and an unapproved combination is a common cause of registration rejection.

Red flags to watch for

Manufacturer shows individual molecule approvals, not combination approval  ·  Ratio doesn’t match your exact formulation  ·  Combination appears on Section 26A restricted list  ·  No clarity on how long the FDC approval has been active

Dissolution Data

Request dissolution and bioequivalence data appropriate to the dosage form

Consistent blood levels matter more for chronic cardiovascular therapy than for acute-use medicines.

#3 of 6

For modified-release cardiovascular formulations especially, request dissolution profile data across time points, and ask what bioequivalence data exists relative to the reference product. This matters more for cardiovascular drugs than acute-use medicines given the clinical importance of consistent blood levels over long-term therapy.

Why bioequivalence data carries extra weight in this category
Cardiovascular medicines often have a narrower therapeutic window than acute-use products — meaning the difference between too little and too much active ingredient in the bloodstream matters clinically. Bioequivalence data relative to the reference (originator) product gives buyers and regulators confidence the generic performs consistently.

How to verify — step by step

  • Request the full dissolution profile for your specific formulation: Not just a single time-point result.

  • Ask what bioequivalence data exists relative to the reference product: Particularly important for modified-release cardiovascular formulations.

  • Confirm data is from stability batches, not just release batches: Dissolution behaviour can drift over shelf life.

  • Check the data matches your exact strength and combination: Not a similar but different formulation.

Why this check matters for export

Dissolution data is a standard, mandatory component of the Quality module in any CTD/ACTD dossier — its absence, or incompleteness for modified-release cardiovascular products specifically, stalls submission.

Red flags to watch for

Only single time-point dissolution data offered · No stability-batch dissolution data available · EC tablet tested only at one pH condition · Dispersion time exceeds WHO standard for dispersible tablets

From the Compare section

WHO-GMP vs ISO 9001 — why certification type matters for chronic-therapy medicine buyers

For a multi-year cardiovascular supply relationship, WHO-GMP’s rigor around batch documentation and quality control directly protects supply consistency for patients on long-term therapy. ISO 9001 does not carry the same pharmaceutical-specific quality requirements.

Complete COA
WHO-GMP certified facility

Sterility · Bacterial endotoxin · Particulate matter · Assay · pH — all required and documented per WHO-GMP batch release procedure.

  • All tests mandatory for batch release
ISO 9001 only facility

Sterility · Bacterial endotoxin · Particulate matter · Assay · pH — all required and documented per WHO-GMP batch release procedure.

  • Pharma-specific tests not mandated
Read Full Comparison

Certificate of Analysis

Request a sample Certificate of Analysis within 24 hours — and know what to look for

Consistent batch-to-batch quality matters more for chronic-use medicines than for one-time-use products.

#4 of 6

Ask for assay, dissolution, hardness, friability, and uniformity data specifically. Given the chronic-use nature of cardiovascular medicines, consistent batch-to-batch quality matters significantly — a manufacturer’s COA responsiveness is a good proxy for their ongoing quality discipline over a multi-year relationship.

What a complete cardiovascular COA must contain

Beyond standard tablet parameters, ask specifically whether batch-to-batch assay consistency data is available — for a patient on long-term therapy, even minor batch-to-batch variation in potency compounds over years of continuous use in a way it doesn’t for short-course medicines.

How to verify — step by step

  • Request a real sample COA: From an actual recent batch, not a template.

  • Ask about batch-to-batch consistency data if available: Relevant specifically for narrow therapeutic window medicines.

  • Confirm numerical values, not just pass/fail: Every parameter should show the actual result obtained.

  • Verify the signing authority: Should be signed by a Qualified Person or pharmacist.

Parameter Why It Matters
Assay (potency) Confirms active ingredient at label strength — batch consistency critical
Dissolution Confirms consistent release rate, especially for modified-release
Hardness/Friability Confirms tablet integrity through handling and transport
Uniformity of weight Confirms consistent dosing — critical for narrow therapeutic window drugs

Why this check matters for export

International regulators require actual numerical results — for cardiovascular products specifically, batch-to-batch consistency data supports the ongoing safety case for a chronic therapy product.

Red Flags to Watch For
COA not available within 24 hours  ·  COA is a blank template  ·  No batch-to-batch consistency discussion available  ·  COA shows only pass/fail without values

Export References

Ask for export references and COPP in your specific target country

Cardiovascular medicines are often part of national essential medicines lists — ask about relevant procurement experience.

#5 of 6

An existing COPP for your target market shortens registration by 6–12 months. Given cardiovascular medicines are typically part of national essential medicines lists, ask specifically whether the manufacturer has supplied similar chronic-therapy products to government procurement or NHM-type programmes — this experience often signals stronger documentation discipline.

What is a COPP (Certificate of Pharmaceutical Product)?
A COPP is issued under the WHO Certification Scheme by CDSCO for products manufactured by a DCGI-licensed manufacturer at a WHO-GMP certified facility. For cardiovascular products specifically, confirm the COPP references your exact molecule and combination. (WHO Technical Report Series No. 986, Annex 10)

How to verify — step by step

  • Ask “Have you previously exported this cardiovascular product to [country]?” — request the specific product name and year of first registration.

  • Ask “Do you hold an active COPP for [country]?” — confirm it matches your exact molecule and combination.

  • Ask about government procurement or NHM-type programme experience: This often signals stronger documentation and supply discipline.

  • Request a CTD or ACTD dossier if available: Export-experienced manufacturers typically hold ready dossiers.

Why this check matters for export
Cardiovascular medicines being part of essential medicines lists means registration authorities may apply additional scrutiny to supply continuity commitments, not just initial product quality — export references specific to this category carry extra weight.

Red flags

Vague answers about prior export experience  ·  COPP offered doesn’t match your specific molecule or combination  ·  No CTD/ACTD dossier despite claimed export history  ·  No experience with essential medicines or institutional procurement programmes

Supply Consistency

Ask for repeat-order references — a single successful shipment tells you less than a track record

Cardiovascular medicine is a long-term relationship, not a one-time transaction — verify accordingly.

#6 of 6

Because cardiovascular medicine is a long-term, repeat-order relationship rather than a one-time transaction, ask directly for references from buyers who have placed multiple consecutive orders. Consistent long-term supply relationships are a stronger signal than a single successful shipment.

Why this final check matters more here than in most other categories
A manufacturer can execute one excellent shipment through focused attention, and still struggle to maintain the same quality and reliability across the third, sixth, or tenth repeat order once the relationship becomes routine. For a chronic-therapy product where patients depend on continuous availability, this distinction has real clinical and reputational consequences for you as the importing buyer.

How to verify — step by step

  • Ask for references specifically from repeat-order buyers: Not just their single best case study.

  • Ask how order-to-order consistency is maintained operationally: Batch review processes, quality trend monitoring, etc.

  • Ask what happens if a batch doesn’t meet specification: A manufacturer with a clear, honest answer here is more trustworthy than one who claims it never happens.

  • Discuss a realistic long-term supply commitment structure: Understanding how the relationship is expected to evolve over multiple years.

Why this check matters for export
An interruption in cardiovascular medicine supply — for a government programme, hospital, or pharmacy chain — has a much higher clinical and reputational cost than a similar interruption for a short-course, acute-use product.

Red Flags to Watch For
Only single-shipment success stories offered as references  ·  No willingness to connect with a genuine repeat-order buyer  ·  Vague or evasive answers about batch failure handling  ·  No clear process for maintaining quality consistency across repeat orders

More Pharma Guide

Frequently asked questions

  • How do I verify a WHO-GMP certificate for an Indian tablet manufacturer?

    Request the actual certificate on CDSCO letterhead showing facility name, site address, licence number, dosage forms covered, issue date, and expiry date. Cross-reference at cdsco.gov.in.

    Reference: Central Drugs Standard Control Organisation (CDSCO)

  • What is the difference between plain, EC, and FDC tablet DCGI approvals?

    DCGI approval is dosage-form specific. Plain tablet approval for a molecule does not extend to its enteric-coated or FDC version — each requires a separate DCGI manufacturing licence referencing the exact dosage-form variant.

  • What should a tablet Certificate of Analysis contain?

    A complete COA shows batch number, dates, assay, dissolution, hardness, friability, uniformity of weight, microbial limits, and the signature of the releasing Qualified Person — with actual numerical results, not just pass/fail.

    British Pharmacopoeia 2024

  • How long does it take to get a COPP for a tablet product from India?

    A fresh COPP application typically takes 30–90 days. Manufacturers with prior export experience to a specific country typically hold active COPPs providable within 24–48 hours.

    WHO Technical Report Series No. 986, Annex 10

  • What is a restricted FDC combination under Section 26A?

    Section 26A of the Drugs and Cosmetics Act, 1940 allows the Indian government to prohibit manufacture and sale of certain fixed-dose combinations found to lack therapeutic justification. Always confirm your specific combination is not on the restricted list before ordering.

9M India — passes all 6 checks

Ready to verify 9M India against your checklist?

WHO-GMP certificate, DCGI approval, sample COA, COPP, stability data — all available within 24 hours of your first enquiry.

Send an enquiry
View Tablet range
WhatsApp

WHO-GMP certified · DCGI approved · 15+ export countries · Birkoni, Chhattisgarh · Est. 2009

By Formulation Type
Tablets Capsules Granules & Powders Syrups Suspensions Solutions Ointments Creams Gels Injections Eye Drops Ear Drops External Liquid Dosage
By Therapeutic Segment
Antibiotics Pain Management Cardiovascular Diabetic Care CNS / Neurology Gastrointestinal Respiratory Dermatology Vitamins & Minerals Ophthalmic Paediatrics Anti Infective

Looking for something specific?

At 9M India Limited, trust through quality, transparency, performance.

Get In Touch With Us

Contract Manufacturing

Contract Manufacturing

3rd Party Manufacturing

3rd Party Manufacturing

Institutional Tenders

Institutional Tenders

Generic Medicines

Generic Medicines

OTC Products

OTC Products

Regulatory Services

QC & QA